AR124522A1 - COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEÍNA SPIKE DEL SARS-CoV-2 - Google Patents
COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEÍNA SPIKE DEL SARS-CoV-2Info
- Publication number
- AR124522A1 AR124522A1 ARP210103681A ARP210103681A AR124522A1 AR 124522 A1 AR124522 A1 AR 124522A1 AR P210103681 A ARP210103681 A AR P210103681A AR P210103681 A ARP210103681 A AR P210103681A AR 124522 A1 AR124522 A1 AR 124522A1
- Authority
- AR
- Argentina
- Prior art keywords
- sars
- cov
- rbd
- subunit
- ndv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención refiere a la obtención de dos vacunas vivas recombinantes o vectorizadas de NDV que expresan la subunidad S1 y RBD de la proteína S del SARS-CoV-2, que al ser aplicada por vía intranasal en modelo de animal hámster genera la producción de anticuerpos neutralizantes contra el SARS-CoV-2. La invención muestra además que estas vacunas vivas son compatibles para su uso combinado entre sí, para inducir la producción de anticuerpos neutralizantes contra el SARS-CoV-2 sin interferencia cruzada sustancial, lo que indica una sinergia entre ambas vacunas, en donde los virus recombinantes de NDV (rNDV-LS1-HN-RBD / SARS-CoV-2 (SEQ ID Nº 7) y rNDVLS1-S1-F / SARS-CoV-2 (SEQ ID Nº 13)), logran expresar la subunidad S1 y RBD de la proteína S del SARS-CoV-2 en mamíferos. Reivindicación 1: Una composición inmunogénica viva recombinante que comprende el virus de la enfermedad de Newcastle (NDV) recombinante que expresa la subunidad S1 y el RBD de la proteína S del SARS-CoV-2 caracterizada porque comprende un virus recombinante denominado rNDV-LS1-HN-RBD / SARS-CoV-2 de SEQ ID Nº 7, un virus recombinante denominado rNDV-LS1-S1-F / SARS-CoV2 de SEQ ID Nº 13 o una mezcla de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PE2021000033A PE20210318A1 (es) | 2021-01-08 | 2021-01-08 | Composicion inmunogenica viva recombinante que comprende el virus de la enfermedad de newcastle (ndv) que expresa la subunidad s1 y el rbd de la proteina spike del sars-cov-2 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR124522A1 true AR124522A1 (es) | 2023-04-05 |
Family
ID=74855966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210103681A AR124522A1 (es) | 2021-01-08 | 2021-12-28 | COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEÍNA SPIKE DEL SARS-CoV-2 |
Country Status (7)
Country | Link |
---|---|
AR (1) | AR124522A1 (es) |
BR (1) | BR112022016492A2 (es) |
CO (1) | CO2022010353A2 (es) |
EC (1) | ECSP22064620A (es) |
MX (1) | MX2022004220A (es) |
PE (1) | PE20210318A1 (es) |
WO (1) | WO2022149058A1 (es) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA016217B1 (ru) * | 2005-12-02 | 2012-03-30 | Маунт Синай Скул Оф Медсин | Химерные вирусы, представляющие неприродные поверхностные белки, и их применение |
WO2021229270A1 (es) * | 2020-05-13 | 2021-11-18 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra covid-19 en vector viral |
CN112011521A (zh) * | 2020-06-15 | 2020-12-01 | 浙江迪福润丝生物科技有限公司 | 一种重组新城疫病毒载体新型冠状病毒疫苗候选株及其构建方法和应用 |
-
2021
- 2021-01-08 PE PE2021000033A patent/PE20210318A1/es unknown
- 2021-12-28 AR ARP210103681A patent/AR124522A1/es unknown
-
2022
- 2022-01-04 BR BR112022016492A patent/BR112022016492A2/pt unknown
- 2022-01-04 WO PCT/IB2022/050031 patent/WO2022149058A1/es active Application Filing
- 2022-01-04 MX MX2022004220A patent/MX2022004220A/es unknown
- 2022-07-22 CO CONC2022/0010353A patent/CO2022010353A2/es unknown
- 2022-08-17 EC ECSENADI202264620A patent/ECSP22064620A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20210318A1 (es) | 2021-02-16 |
BR112022016492A2 (pt) | 2023-10-31 |
WO2022149058A1 (es) | 2022-07-14 |
MX2022004220A (es) | 2022-08-08 |
ECSP22064620A (es) | 2022-09-30 |
CO2022010353A2 (es) | 2022-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023000411A (es) | Vacuna combinada de sars-cov-2 e influenza. | |
CO6460752A2 (es) | Respuesta inmunitaria reforzada en especies aviares | |
US20110171260A1 (en) | Influenza dna vaccination and methods of use thereof | |
PE20141482A1 (es) | Vectores recombinantes de hvt que expresan antigenos de patogenos de aves y sus usos | |
AR109538A1 (es) | Vacuna contra la gripe porcina | |
AR065076A1 (es) | Vacuna contra el papilomavirus | |
CL2021003211A1 (es) | Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018) | |
CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
PE20230171A1 (es) | Vacunas contra el coronavirus y metodos de uso | |
CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
BR112023005043A2 (pt) | Vacina contra covid-19 à base de piv5 | |
AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
AR103427A1 (es) | Vacuna contra la fiebre aftosa | |
RU2021112503A (ru) | Поливалентная вакцина против м. hyo и её применение | |
CL2013002631A1 (es) | Virus de la necrosis pancreatica infecciosa (ipnv) avirulento porque comprende proteina vp2 madura. | |
EA202191145A1 (ru) | Вакцина виб 4/91 с гетерологичным шиповидным белком | |
AR082281A1 (es) | Vectores de parapoxvirus | |
AR124522A1 (es) | COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEÍNA SPIKE DEL SARS-CoV-2 | |
BR112022019207A2 (pt) | Composições de vacina para coronavírus e métodos de uso das mesmas | |
AR105160A1 (es) | Métodos de modulación de moléculas de vigilancia de adn citosólicas | |
CO2023015564A2 (es) | Virus quimérico de la enfermedad de newcastle que expresa las proteínas hn y f del apmv | |
AR048671A1 (es) | Procedimiento de vacunacion contra la infeccion testicular por bvdv | |
AR085800A1 (es) | Vacuna de rinitis equina | |
CO5721019A2 (es) | Aislados y vacunas antigenicos de virus de bursitis infecciosa | |
AR127858A1 (es) | VACUNAS DE ÁCIDOS NUCLEICOS PARA EL CORONAVIRUS BASADAS EN SECUENCIAS DERIVADAS DE LA CEPA ÓMICRON DEL SARS-CoV-2 |